The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

John F Seymour,Lewis R Silverman,Hartmut Döhner,Pierre Fenaux,Ghulam J Mufti,Valeria Santini,Mark D Minden,Richard M Stone,Lela M Lucy,Stephen Songer,Donna Dougherty,Randy Hinkle,Dominique Gambini,C.L Beach,Hervé Dombret

doi:10.1182/blood.v126.23.3754.3754

The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

John F Seymour, Lewis R Silverman + Show 13 more

Open Access

https://doi.org/10.1182/blood.v126.23.3754.3754

Copy DOI

Journal: Blood	Publication Date: Dec 3, 2015
Citations: 2

Affiliation: Peter MacCallum Cancer Centre, Icahn School of Medicine at Mount Sinai, University Hospital Ulm, Délégation Paris 7, Hôpital Saint-Louis, Université Paris Cité, King's College Hospital, University of Florence, Princess Margaret Cancer Centre, University Health Network, Dana-Farber Cancer Institute

#Azacitidine In Pts #Tx-emergent Adverse Events + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.